PMID- 26705179
OWN - NLM
STAT- MEDLINE
DCOM- 20160202
LR  - 20220310
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 44
IP  - 8
DP  - 2015 Aug
TI  - [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse 
      prognostic factors in diffuse large B-cell lymphoma].
PG  - 559-64
AB  - OBJECTIVE: To study expression of CD68, cyclin D1 protein and rearrangement of 
      bcl-6 gene impact on the prognosis of diffuse large B-cell lymphoma (DLBCL). 
      METHODS: Gets paraffin samples of the 105 cases DLBCL with the detailed follow-up 
      information, and were studied by using immunohistochemical EnVision method for 
      CD3, CD10, CD20, CD68, cyclin D1, bcl-6, MUM 1, SOX-11 immunolabeling. The DLBCL 
      were classified into germinal center B cell-like (GCB) subtypes and non-germinal 
      center B cell-like (non-GCB) subtypes according to Hans'algorithm. Application of 
      fluorescence in situ hybridization (FISH) technique to detect the bcl-6 gene 
      rearrangement. The relationship between CD68, cyclin D1 protein, the bcl-6 gene 
      and the curative effect of chemotherapy and survival was analyzed using 
      statistical software. Respectively by GCB type, non-GCB type immune phenotype and 
      CHOP, R-CHOP chemotherapy group, compare the curative effects. RESULTS: 105 
      patients had GCB 19 cases (18.1%), non-GCB 86 cases (81.9%), CD68 expression was 
      18 cases (17.1%), cyclin D1 high expression 36 cases (34.3%), bcl-6 gene 
      rearrangement in 21 cases (21.9%), there is no correlation among the three (P > 
      0.05). One-way analysis of variance showed that age </= 60 years, clinical stage 
      I-II, IPI score 0 to 2 points, LDH (U/L) < 245 IU/L,GCB subtypes, R-CHOP therapy, 
      the prognosis of patients with better (P < 0.05), But gender, primary site no 
      correlation with prognosis (P > 0.05). CD68, cyclin D1 high expression, bcl-6 
      rearrangement had poor prognosis (P < 0.05). Stratification analysis results show 
      GCB-type or non-GCB type with high expression of CD68 contrast alloimmune 
      phenotype groups had a poor prognosis, non-GCB type with high expression of 
      cyclin D1 and rearrangement of bcl-6 gene had a poor prognosis (P < 0.001, P = 
      0.02). Treatment scheme of layered display, the CHOP treatment, significantly 
      correlated with overall survival with high expression of CD68, cyclin D1 (P < 
      0.05), the R-CHOP treatment, there was no statistically significant difference 
      between CD68, cyclin D1 high expression and overall survival (P = 0.428 and 
      0.168). Multivariate COX model analysis showed that high expression of CD68 (P = 
      0.026), high expression of cyclin D1 (P = 0.003) and high levels of LDH (P = 
      0.005) were adverse prognostic factors independent. CONCLUSIONS: high expression 
      of CD68, cyclin D1 and rearrangement of bcl-6 gene suggests poor prognosis, CD68, 
      cyclin D1 protein and bcl-6 gene can be used as a prognostic indicator in 
      patients with DLBCL.
FAU - Liang, Xiaojie
AU  - Liang X
AD  - Department of Pathology, Shanxi Cancer Hospital, Shanxi Medical University, 
      Taiyuan 030013, China.
FAU - Wang, Jinfen
AU  - Wang J
AD  - Department of Pathology, Shanxi Cancer Hospital, Shanxi Medical University, 
      Taiyuan 030013, China; E-mail: jfenw@hotmail.com.
FAU - Bai, Wei
AU  - Bai W
AD  - Department of Pathology, Shanxi Cancer Hospital, Shanxi Medical University, 
      Taiyuan 030013, China.
FAU - Sun, Ruifang
AU  - Sun R
AD  - Department of Pathology, Shanxi Cancer Hospital, Shanxi Medical University, 
      Taiyuan 030013, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (BCL6 protein, human)
RN  - 0 (CCND1 protein, human)
RN  - 0 (CD68 antigen, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (R-CHOP protocol)
RN  - 136601-57-5 (Cyclin D1)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Antibodies, Monoclonal, Murine-Derived
MH  - Antigens, CD/*metabolism
MH  - Antigens, Differentiation, Myelomonocytic/*metabolism
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - B-Lymphocytes/classification
MH  - Cyclin D1/*metabolism
MH  - Cyclophosphamide
MH  - DNA-Binding Proteins/*genetics
MH  - Doxorubicin
MH  - *Gene Rearrangement
MH  - Germinal Center/cytology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Large B-Cell, Diffuse/*diagnosis
MH  - Prednisone
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-bcl-6
MH  - Rituximab
MH  - Vincristine
EDAT- 2015/12/26 06:00
MHDA- 2016/02/03 06:00
CRDT- 2015/12/26 06:00
PHST- 2015/12/26 06:00 [entrez]
PHST- 2015/12/26 06:00 [pubmed]
PHST- 2016/02/03 06:00 [medline]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2015 Aug;44(8):559-64.